BioAge Labs: Virtual KOL event: Positive Ph1b topline muscle atrophy data for BioAge’s first-in-class apelin receptor agonist BGE-105 & Ph2 design for prevention of acute ICU myopathies in older patients
About The Event
Join us for a virtual KOL Event with BioAge Labs, featuring William J. Evans, PhD (UC Berkeley & Duke University) and Ewan Goligher, MD, PhD, FRCPC (Toronto General Hospital). Dr. Evans and Dr. Goligher will provide an overview of the clinical impact and current treatment landscape for conditions related to muscle aging, including the significant unmet medical need for therapies for intensive care unit (ICU) diaphragmatic atrophy and critical illness myopathy. Patients undergoing mechanical ventilation in the ICU undergo rapid disuse atrophy of the diaphragm and peripheral muscles, which results in adverse outcomes ranging from long recovery time to substantially increased mortality. No therapies are available for either condition.
BioAge leadership will present the positive topline results from a Phase 1b trial investigating the safety and efficacy of BGE-105, an oral agonist of the apelin receptor APJ, for muscle atrophy in older patients and provide insight into the design of a Phase 2 trial for prevention of ICU diaphragmatic atrophy and critical illness myopathy.
A live Q&A session will follow the live presentations.
For more information click here for press release.
About Our Speakers:
William J. Evans, PhD is Adjunct Professor of Human Nutrition at UC Berkeley and Medicine (Geriatrics) at Duke University. With an h-index of 120, he is the author or co-author of more than 300 publications and was the first to describe sarcopenia, the age-related loss of muscle mass and strength that drives functional decline and loss of independence in older adults. His research has examined the effects of bed rest on body composition, muscle metabolism and functional capacity in older people, biomarkers for changes in muscle mass and function, and the etiology of late life dysfunction, and has revealed connections between sarcopenia and other diseases of aging. Previously, he was President of the Muscle and Health Division at KineMed and VP and Head of GlaxoSmithKline’s Muscle Metabolism Discovery Performance Unit. In 2005, he testified before the Senate Select Committee on Aging about strategies to save Medicare through prevention of chronic diseases associated with aging.
Ewan Goligher, MD, PhD, FRCPC is an internationally recognized expert in critical care medicine and a leader in the field of lung and diaphragm injury during mechanical ventilation (MV). His research at the University of Toronto and University Health Network has contributed significantly to the field of diaphragm dysfunction, including the development of novel ultrasound techniques for assessing diaphragm muscle structure and function in patients on MV. He has extensive experience leading clinical trials, including a study that characterized diaphragmatic changes in mechanically ventilated patients, resulting in the seminal description of the prevalence of diaphragm atrophy and injury during MV. He was the first to describe the relationship between changes in diaphragm thickness and the risk of complications of respiratory failure, including prolonged ventilation, reintubation, and tracheostomy, and first to propose the concepts of diaphragm myotrauma and diaphragm-protective ventilation.